Inflammatory bowel disease (IBD) is treated with a combination of medications designed to calm inflammation, maintain remission, and prevent flare-ups. The two main forms, Crohn’s disease and ulcerative colitis, share some treatments but differ in key ways, especially when it comes to surgery and diet. Most people with IBD will need some form of ongoing therapy, and the specific approach depends on disease severity, location, and how the body responds over time.
How Treatment Strategy Is Chosen
IBD treatment follows one of two broad philosophies. The traditional approach starts with milder medications and escalates to stronger ones only when needed. The alternative, sometimes called “top-down” therapy, begins with powerful medications right away. Top-down therapy is generally considered for people with complicated disease, poor prognostic factors like being diagnosed young, needing repeated steroid courses, or having signs of aggressive disease such as perianal involvement or visible bowel damage.
Your gastroenterologist will weigh these factors when building a treatment plan. The goal in either approach is the same: get inflammation under control quickly (called induction) and then keep it suppressed long-term (maintenance).
Medications for Mild Disease
For mild ulcerative colitis, a class of anti-inflammatory drugs called aminosalicylates is the usual starting point. These come as oral tablets, enemas, or suppositories, and they work directly on the lining of the colon. They’re effective for many people with mild to moderate UC but play a smaller role in Crohn’s disease.
Corticosteroids like prednisone are commonly used as short-term rescue therapy during flares. They suppress inflammation broadly and work fast, but they carry significant side effects with prolonged use, including bone loss, weight gain, and mood changes. Steroids are a bridge, not a long-term solution. If you find yourself needing repeated steroid courses, that’s typically a signal to move to a stronger maintenance medication.
Biologic Therapies
Biologics are lab-made proteins that target specific parts of the immune system driving intestinal inflammation. They’ve transformed IBD care over the past two decades. Several classes are now available, each blocking a different inflammatory pathway.
TNF blockers were the first biologics approved for IBD. They work by neutralizing a key inflammatory protein called tumor necrosis factor-alpha. Options include infliximab (given by IV infusion), adalimumab (a self-injection), and certolizumab pegol (also a self-injection). In clinical trials of infliximab for ulcerative colitis, about 65 to 67% of patients who had never tried a biologic achieved a clinical response within eight weeks. Sustained remission at one year, however, was closer to 35%, highlighting that response and long-term remission are different benchmarks.
Integrin blockers prevent inflammatory white blood cells from migrating into gut tissue. Vedolizumab is the most commonly used in this class and is considered gut-selective, meaning it targets intestinal inflammation without broadly suppressing the immune system elsewhere.
IL-12/23 and IL-23 blockers are newer options. Ustekinumab blocks both IL-12 and IL-23, while risankizumab, guselkumab, and mirikizumab target IL-23 more specifically. These are used in both Crohn’s disease and ulcerative colitis.
How Biologics Are Ranked
Not all biologics perform equally. The American Gastroenterological Association’s 2024 guideline for moderate-to-severe UC categorizes advanced therapies by efficacy. For people who haven’t tried a biologic before, higher-efficacy options include infliximab, vedolizumab, upadacitinib, risankizumab, and guselkumab. Adalimumab, once widely used as a first-line biologic, is now classified as lower-efficacy for UC. In trials, only about 22% of biologic-naive patients on adalimumab achieved remission at one year, compared to roughly 35% on infliximab.
For people who’ve already tried one or more biologics without success, the ranking shifts. Tofacitinib, upadacitinib, and ustekinumab are considered higher-efficacy in this setting, while vedolizumab drops to the lower tier. This matters because prior biologic exposure tends to reduce the odds of responding to the next therapy, so choosing a potent option becomes more important.
Small Molecule Oral Therapies
A newer wave of IBD medications comes in pill form rather than injections or infusions. These small molecules are absorbed through the gut and work inside cells to interrupt inflammatory signaling.
JAK inhibitors block enzymes called Janus kinases that relay inflammatory signals within immune cells. Tofacitinib and filgotinib are approved for ulcerative colitis, while upadacitinib is approved for both UC and Crohn’s disease. These tend to work relatively quickly, and their oral dosing is a practical advantage for people who want to avoid needles or infusion centers.
S1P receptor modulators, including ozanimod and etrasimod, work differently. They trap certain immune cells in lymph nodes, preventing them from traveling to the gut and causing inflammation. Both are approved for ulcerative colitis. These oral medications expand the toolkit considerably for UC patients, though Crohn’s disease has fewer oral options so far.
When Surgery Becomes Necessary
Surgery enters the picture when medications fail to control symptoms, when complications develop, or when the risks of continued medical therapy outweigh the risks of an operation. The indications and procedures differ between Crohn’s disease and ulcerative colitis.
Surgery for Crohn’s Disease
Crohn’s disease most commonly requires surgery for fistulas (abnormal tunnels between the bowel and other structures), abscesses, and bowel obstruction from scarring. Less commonly, surgery is needed for perforation or severe bleeding. The most straightforward approach is removing the diseased section of bowel and reconnecting the healthy ends.
For people with multiple narrowed segments, a procedure called stricturoplasty can widen the bowel without removing any of it. This is especially useful when prior surgeries have already shortened the intestine. Because Crohn’s disease can recur after surgery, the goal is to preserve as much bowel length as possible.
Surgery for Ulcerative Colitis
Unlike Crohn’s, ulcerative colitis is limited to the colon and rectum, which means removing the entire colon can be curative. The most common procedure creates an internal pouch from the end of the small intestine (often called a J-pouch) that connects to the anus, allowing relatively normal bowel function without a permanent external bag. Some people do require a permanent ileostomy instead, depending on their anatomy and circumstances.
The Role of Diet
Diet alone doesn’t replace medication for most people with IBD, but specific dietary strategies can reduce symptoms and, in some cases, help control inflammation directly.
The Crohn’s Disease Exclusion Diet (CDED) is the most studied structured diet for IBD. It works in three phases. Phase 1 (weeks one through six) is highly restrictive, eliminating foods and additives that may damage the gut lining or disrupt the microbiome. It emphasizes lean proteins like chicken breast and eggs, along with resistant starch sources like potatoes and fiber from bananas and apples. Phase 2 (weeks six through twelve) gradually reintroduces previously restricted foods. Phase 3 begins at week thirteen and continues for at least nine months as a more personalized maintenance plan.
For people with narrowed areas of bowel, a dietitian may recommend modified food textures to reduce the risk of blockages. And for those with overlapping irritable bowel symptoms, a low-FODMAP approach can be layered on top, temporarily reducing fermentable sugars from foods like garlic, onions, and apples that may worsen bloating and cramping even though they aren’t driving the underlying inflammation.
Curcumin as an Add-On Therapy
Curcumin, the active compound in turmeric, has been studied as a supplement alongside standard IBD medications. A meta-analysis of randomized controlled trials found that curcumin roughly doubled the likelihood of achieving clinical remission and response in ulcerative colitis patients compared to placebo. It also significantly improved endoscopic healing, meaning the bowel lining looked better on colonoscopy.
The picture is different for Crohn’s disease. Across the available trials, curcumin did not outperform placebo for either clinical or endoscopic remission in Crohn’s patients. The evidence is limited to only two randomized trials, so the data is thin, but what exists isn’t encouraging.
Doses used in studies ranged widely, from around 150 milligrams to 3 grams per day, with treatment lasting one to six months. Side effect rates were essentially identical between curcumin and placebo groups, making it a low-risk option for UC patients interested in complementary approaches. It should be used alongside standard therapy, not as a replacement.
Tracking Disease Activity
One of the challenges of IBD is that symptoms don’t always match what’s happening inside the bowel. You can feel relatively well while inflammation quietly progresses, or you can have bothersome symptoms from irritable bowel overlap while your IBD is actually in remission. That’s why objective monitoring matters.
A stool test for a protein called fecal calprotectin is the most practical non-invasive way to gauge intestinal inflammation. In ulcerative colitis, a level below roughly 191 micrograms per gram predicts endoscopic remission with about 88% sensitivity. In Crohn’s disease, the thresholds tend to be higher and less precise, but tracking trends over time is still useful. Rising calprotectin levels can signal a flare before symptoms appear, giving you and your doctor a window to adjust treatment proactively rather than reactively.
Colonoscopy remains the gold standard for assessing mucosal healing, but calprotectin testing can space out the need for repeated scopes and help guide decisions between appointments.